Existing backer GV returned to take part in a $100m round for the clinical data software provider that also attracted new investor Regeneron Pharmaceuticals.

US-based health informatics technology developer DNAnexus closed a $100m funding round yesterday backed by biotechnology firm Regeneron Pharmaceuticals and GV, an early-stage investment subsidiary of internet and technology conglomerate Alphabet. Investment management firm Perceptive Advisors and venture capital firm Northpond Ventures co-led the round, which also featured Foresite Capital, TPG Capital and First Round Capital.…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.